Adcendo ApS
ADCE-T02(Adcendo ApS)은 Advanced Solid Tumor 표적 ADC로, Advanced Solid Tumor 영역에서 개발·상용화 중입니다. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the Topoisomerase-1 inhibit.
Advanced Solid Tumor
Advanced Solid Tumor
Recruiting
ADCE-T02 - a Next Generation Antibody Drug Conjugate Targeting
vedotin is approved for cervical cancer treatme
linker to the Topoisomerase-1 inhibitor Exatecan at an average drug-to-antibody ratio
novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the Topoisomerase-1 inhibit
Topoisomerase-1 inhibitor Exatecan at an average drug-to-antibody ratio of 4
resistance to standard of care, low and/or heterogeneous expression of TF, and multi-drug resistance
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Adcendo ApS
ADCE-T02(Adcendo ApS)은 Advanced Solid Tumor 표적 ADC로, Advanced Solid Tumor 영역에서 개발·상용화 중입니다. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the Topoisomerase-1 inhibit.
Advanced Solid Tumor
Advanced Solid Tumor
Recruiting
ADCE-T02 - a Next Generation Antibody Drug Conjugate Targeting
vedotin is approved for cervical cancer treatme
linker to the Topoisomerase-1 inhibitor Exatecan at an average drug-to-antibody ratio
novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the Topoisomerase-1 inhibit
Topoisomerase-1 inhibitor Exatecan at an average drug-to-antibody ratio of 4
resistance to standard of care, low and/or heterogeneous expression of TF, and multi-drug resistance
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.